PET imaging to guide HER2 breast cancer treatment sequencing
Treatments studied
Part of Cancer clinical trials.
This study tests whether a special PET scan using a radioactive tracer can help doctors choose the right sequence of antibody-drug conjugates for HER2-positive advanced breast cancer. It is for patients whose cancer has already progressed on the drug T-DXd (Enhertu).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has spread or is advanced.
- You have already been treated with T-DXd (Enhertu) and your cancer still grew while on it.
- You are well enough to be up and about (ECOG score 0 or 1).
- You must have at least two tumors that are big enough and active enough to be seen on a scan.
- Your heart, kidneys, liver, and blood counts are healthy enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.